The ongoing DEPROMP trial39 will firstly evaluate the impact of adding PSMA PET/CT‐guided prostate biopsy to standard of care methods (systematic biopsy and MR‐guided biopsy) in 230 biopsy‐naïve patients providing data on tumour detection, risk stratification and the need for multiple biopsies. The gene discussed is FOLH1; the disease is neoplasm.